Glucagon itself generally raises glucose, but potent incretin-based therapies can lower glucose substantially, especially when combined with insulin or sulfonylureas
Starting dose should be 0.20.3 mg/kg/day and increases of 510 mg/week should be done up to the highest dose of 11.5 mg/kg/day (79, 156)
As someone familiar with ingredient sourcing challenges, I recognize how valuable it can be for a manufacturer to maintain strong relationships with local suppliers of botanical ingredients, because this often leads to greater traceability and consistency in raw material quality
Diabetes should be well-managed before starting therapy Active pituitary tumors: Stimulating a gland with an active tumor is contraindicated Monitoring Requirements Safe use of CJC-1295/Ipamorelin requires ongoing physician monitoring: Baseline labs: IGF-1, fasting glucose, HbA1c, thorough metabolic panel, CBC 4-6 week follow-up: IGF-1 to confirm dose response
Fat loss is especially challenging for women, who face unique hormonal battles
